कंपनी का अवलोकन
Pacific Biosciences of California, Inc. (PACB) operates within the Healthcare sector specifically focused on the Medical Devices industry, where it designs, develops, and manufactures sequencing solutions intended to resolve genetically complex problems. The company's product portfolio includes sequencing systems, single molecule real-time (SMRT) technology consumables, long-read sequencing capabilities, and various reagent kits that support these advanced biological applications. This entity employs a workforce of 485 individuals and holds a market capitalization of $443.94M, while reporting a Trailing Twelve Months (TTM) revenue of $160.00M. The market cap figure of $443.94M combined with the annual revenue of $160.00M indicates a mid-sized enterprise operating in a high-technology niche, suggesting a position that balances established product revenue streams with the capital-intensive nature of medical device development and manufacturing.
वित्तीय स्वास्थ्य
The company reported a TTM revenue of $160.00M, yet simultaneously recorded a net income loss of $546,376,000 and an EBITDA of $-169,226,000. The substantial gap between the positive revenue of $160.00M and the significant negative net income reveals a cost structure where operating expenses and other deductions vastly exceed gross profits, resulting in a net loss that is nearly four times the magnitude of the revenue generated. Despite the reported earnings loss, the firm maintains a free cash flow of $97.55M, which indicates a degree of financial flexibility allowing the company to fund operations and potentially invest in R&D without immediate reliance on external financing for cash preservation. The company's margin profile presents a complex picture with a gross margin of 34.3%, contrasting sharply with an operating margin of -134.5% and a profit margin of 0.0%. The negative operating margin indicates that selling, general, and administrative expenses, along with research and development costs, are so high that they not only consume the gross profit but also generate additional losses, while the 0.0% profit margin confirms the absence of net profitability on a bottom-line basis. On the liability side, Pacific Biosciences of California, Inc. holds $279.51M in cash against total debt of $702.42M, resulting in a debt-to-equity ratio of 13131.84, which characterizes the balance sheet as highly leveraged given the overwhelming debt relative to equity. The current ratio stands at 5.15, suggesting that the company possesses substantial current assets relative to its current liabilities, indicating strong short-term liquidity capabilities that could be utilized to service debt obligations or manage working capital needs. Return on Equity is reported at -213.5% and Return on Assets at -33.7%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in terms of generating positive returns, likely due to the heavy investment phases or restructuring costs inherent to the medical device sector.
मूल्यांकन आकलन
Valuation metrics for Pacific Biosciences of California, Inc. display a distinct divergence between historical performance and future expectations, with a Trailing P/E Ratio (TTM) listed as N/A due to negative earnings and a Forward P/E of -3.56. The presence of a negative forward P/E implies that the market prices the stock based on anticipated future earnings that are expected to turn positive or based on revenue multiples rather than current profitability, highlighting a high-risk valuation model dependent on future operational turnaround. The Price to Book ratio is an exceptionally high 81.67, indicating that the market values the company's equity at a massive premium over its book value, which often reflects expectations of future growth or intangible asset value that is not captured on the balance sheet. Alternative valuation measures such as the Price to Sales ratio of 2.77 and an EV/EBITDA of -5.12 provide context for investors, as these metrics suggest the stock is priced based on top-line growth potential and enterprise value multiples rather than earnings power. The stock's recent trading range is defined by a 52-Week High of $2.73 and a 52-Week Low of $0.85, placing the current valuation context within a volatile band that spans over three times the low point. The Beta value of 2.33 indicates that the stock price is expected to be significantly more volatile than the broader market, with price movements roughly 2.33 times greater than market fluctuations, which underscores the high risk profile associated with investing in this biotechnology and medical device firm.
Growth & Income
Pacific Biosciences of California, Inc. demonstrated a Revenue Growth (YoY) of 13.8%, while Earnings Growth (YoY) is marked as N/A due to the company's continued negative net income. The disparity between positive revenue growth and the absence of earnings growth implies that the company is successfully expanding its top line but is still burdened by high costs that prevent the realization of profitable earnings growth. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that the firm does not distribute cash to shareholders but instead retains all earnings to reinvest into growth initiatives, research, and development. This reinvestment strategy is typical for early-stage or high-growth medical device companies that prioritize expanding their product portfolio and technological capabilities over providing immediate income to investors. The overall growth and income profile reflects a classic growth-stage capital structure where capital appreciation is the primary return mechanism, supported by strong revenue expansion but lacking current profitability or dividend income streams.